Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

From psoriasis to PsA: risk, early signs and prevention

How to think about future arthritis without treating a risk factor as a diagnosis. The aim is to recognise a meaningful change early and understand what prevention studies are testing.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 18 of 21

The essentials

Psoriasis does not inevitably lead to arthritis. Early recognition and treatment of established PsA are valuable; proving that an intervention prevents its first onset requires a different kind of study.

A risk factor changes probability

Nail disease, greater psoriasis burden, excess weight and family history can contribute to a risk assessment. They do not form a countdown to arthritis. The background population and the time period matter whenever a percentage is quoted. 1, 4

Ask what the estimate refers to: risk over the next year, several years or an entire lifetime? A number from a specialist clinic may not apply to everyone with mild psoriasis.

Symptoms worth documenting

Record new joint swelling, prolonged stiffness after rest, swelling of a whole finger or toe, or persistent pain around a tendon attachment. Note when it began, whether swelling was visible and what activities changed. A dated photograph can help with intermittent swelling. 2

Symptoms deserve assessment even when skin disease is mild or well controlled. They can have other causes, so a screening questionnaire prompts evaluation rather than confirming PsA.

What does subclinical mean?

EULAR describes higher-risk psoriasis, a subclinical phase and clinical PsA as useful research categories. Arthralgia—joint pain—and imaging abnormalities may help identify groups for closer study. These are not compulsory steps through which every person passes. 4

An ultrasound or MRI finding must be interpreted at the correct site and in context. Mechanical loading and other conditions can also produce abnormalities. An isolated scan finding does not automatically justify a PsA label or a preventive drug.

What can be done now—and what is being tested?

Treat psoriasis appropriately, maintain achievable physical activity, address excess weight without blame and report new musculoskeletal symptoms. These actions support health and timely care; they do not guarantee prevention of PsA. 1, 2

PAMPA asks whether targeting IL-23 with guselkumab can alter progression in a selected at-risk population. Its protocol describes the question and methods; a protocol is not a positive trial result. The registry is linked so readers can check subsequent reports. 5, 6

A useful follow-up agreement

Agree who will assess new symptoms, how to obtain an appointment and what would trigger earlier review. Follow-up should have a purpose: recognising a change that would alter management. Repeating tests without a decision attached may create uncertainty rather than clarity.

If PsA is already present, prompt disease control aims to limit damage and preserve function. That is treatment of established disease, distinct from preventing the first episode. 3

Go deeper

Why observational prevention claims need care

Suppose treated and untreated psoriasis groups develop arthritis at different rates. They may also differ in disease severity, access to specialists, previous symptoms and how actively arthritis is sought. Statistical adjustment helps, but cannot remove every difference.

Random assignment can strengthen causal inference. A convincing prevention study must also define the starting population, how new PsA is confirmed, duration of follow-up and harms. HPOS is a prospective observational project designed to study risk factors; its 2026 protocol does not establish a preventive treatment. 17

Questions for your visit

  1. Which new symptoms should change my follow-up plan?
  2. Does this scan finding fit my symptoms and examination?
  3. Is this treatment intended for my current disease or offered within a prevention study?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Dates identify the cited publications. Protocols, exploratory analyses and clinical results answer different questions. This is a selected reading route, not a complete evidence review.

  1. NIAMS. Psoriatic arthritis: overview and causes.
  2. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  3. EULAR recommendations for PsA: 2023 update (published 2024).
  4. Zabotti et al. EULAR points to consider: progression from psoriasis to PsA (2023).
  5. Haberman et al. PAMPA prevention trial protocol (2022; correction 2023).
  6. ClinicalTrials.gov. PAMPA, NCT05004727. Live registry record.
  7. Grohmann et al. HIPPOCRATES Prospective Observational Study protocol (2026).

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medical researchPsoriasisPsoriatic arthritisSpondyloarthritis